Noradrenalin (Norepinephrin) Aguettant (Noradrenaline Tartrate)

Noradrenaline activates alpha‑1, alpha‑2 and beta‑1 adrenergic receptors. Alpha‑1 stimulation causes peripheral vasoconstriction, raising systemic vascular resistance; alpha‑2 reduces sympathetic release, modulating tone; beta‑1 increases heart rate and contractility, together supporting circulation in shock states.

The dose of Noradrenalin is individualized. A qualified prescriber determines the infusion rate based on the patient’s hemodynamic status, target blood‑pressure goals and response to therapy, adjusting continuously during treatment.

Safety data for Noradrenalin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and required import documentation.

Noradrenalin is the preferred first‑line vasopressor for most forms of shock because it provides potent alpha‑mediated vasoconstriction with modest beta‑1 activity. Dopamine has dose‑dependent effects and may cause more tachyarrhythmias, while epinephrine adds strong beta‑2 stimulation, which can increase lactate production and myocardial oxygen demand.

Noradrenalin injection must be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and inspect for particulate matter before administration.

The drug is given intravenously, usually via a calibrated infusion pump. It is administered through a central venous catheter or a well‑secured peripheral line, with continuous hemodynamic monitoring to titrate the infusion to the desired blood‑pressure target.

Serious risks include severe hypertension, myocardial ischemia, arrhythmias, tissue necrosis from extravasation, and rare anaphylactic reactions. Prompt recognition and management of these events are essential, and infusion sites should be inspected regularly.

Noradrenalin is contraindicated in patients with known hypersensitivity to the product, those with untreated pheochromocytoma, and individuals with uncorrected hypovolemia where vasoconstriction could worsen tissue perfusion.